Toxicity and Effect of Preoperative Chemoradiotherapy with XELOX on The Treatment of Advanced Mid-Low Rectal Cancer

Objective To explore the toxicity and efficacy of neoadjuvant chemoradiotherapy with XELOX on the treatment for patients of advanced mid-low rectal cancer. Methods From June 2014 to December 2016, 75 patients with advanced mid-low rectal cancer were treated in the gastroenterology department of Guangdong General Hospital,whose data were retraspective analysed. The patients received neoadjuvant chemotherapy of XELOX every 3 weeks for 3 cycles combined with neoadjuvant radiotherapy. Results 2 cases drop-out and 1 case quited chemoradiotherapy because of serious adverse events. 72 patients received complete chemoradiotherapy, of which 71 received TME operation and 1 occured metastases. A total of 173 times of adverse reaction occured, of which 20 were ≥ grade 3. Tumor markers in these patients had a downward trend. After neoadjuvant therapy, patlogy complete response happened in 16 cases （22.2%）, partial response in 49 cases （68.1%）, stable disease in 6 cases （8.3%）, progression in 1 cases （1.4%）, the response rate was 89.0%. Conclusion Preoperative chemoradiotherapy with XELOX for patients with advanced mid-low rectal cancer is safe and effective.